Skip to main content
SpringerLink
Log in

Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group remains challenging. In this retrospective study, we aimed to compare outcome in elderly patients treated with different post-remission modalities, including allogenic and autologous hematopoietic stem cell transplantation (HSCT), intensive chemotherapy, and standard-dose chemotherapy (repeated 1 + 5 regimen). We collected data of 441 patients ≥ 60 years in first CR from a single institution. Median age was 67 years. Sixty-one (14%) patients received allo-HSCT, 51 (12%) auto-HSCT, 70 (16%) intensive chemotherapy with intermediate- or high-dose cytarabine (I/HDAC), and 190 (43%) 1 + 5 regimen. Median follow-up was 6.5 years. In multivariate analysis, allo-HSCT, cytogenetics, and PS had a significant impact on OS and LFS. In spite of a more favorable-risk profile, the patients who received I/HDAC had no significantly better LFS as compared with patients treated with 1 + 5 (median LFS 8.8 months vs 10.6 months, p = 0.96). In transplanted patients, median LFS was 13.3 months for auto-HSCT and 25.8 months for allo-HSCT. Pre-transplant chemotherapy with I/HDAC had no effect on the outcome. Toxicity was significantly increased for both transplanted and non-transplanted patients treated with I/HDAC, with more units of blood and platelet transfusion and more time spent in hospitalization, but no higher non-relapse mortality. This study shows that post-remission chemotherapy intensification is not associated with significantly better outcome as compared with standard-dose chemotherapy in elderly patients for whom, overall results remain disappointing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

    Article  Google Scholar 

  2. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924–1930

    Article  CAS  Google Scholar 

  3. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331(14):896–903

    Article  CAS  Google Scholar 

  4. Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet Lond Engl 368(9550):1894–1907

    Article  Google Scholar 

  5. Estey EH (2000) How I treat older patients with AML. Blood 96(5):1670–1673

    Article  CAS  Google Scholar 

  6. Fröhling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Döhner K et al (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 108(10):3280–3288

    Article  Google Scholar 

  7. Etienne A, Esterni B, Charbonnier A, Mozziconacci M-J, Arnoulet C, Coso D et al (2007) Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 109(7):1376–1383

    Article  Google Scholar 

  8. Vey N (2013) Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress? Interdiscip Top Gerontol 38:73–84

    Article  Google Scholar 

  9. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94(3):1086–1099

    CAS  PubMed  Google Scholar 

  10. Pigneux A, Béné MC, Guardiola P, Recher C, Hamel J-F, Sauvezie M et al (2016) Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study. J Clin Oncol 35(4):387–393

    Article  Google Scholar 

  11. Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R1, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C, French Innovative Leukemia Organization (2018) Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.7366

    Article  CAS  Google Scholar 

  12. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N et al (2007) Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109(12):5129–5135

    Article  CAS  Google Scholar 

  13. Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E et al (2011) Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria. Haematologica 96(6):837–844

    Article  CAS  Google Scholar 

  14. Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ et al (2019) Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood 133(13):1457–1464

    Article  CAS  Google Scholar 

  15. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie J-N et al (2012) Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379(9825):1508–1516

    Article  CAS  Google Scholar 

  16. Vey N, Dumas P-Y, Recher C, Gastaud L, Lioure B, Bulabois C-E et al (2017) Randomized phase 2 trial of lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly patients (pts) with acute myeloid leukemia (AML): results of the Effikir trial. Blood 130(Suppl 1):889–889

    Google Scholar 

  17. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP et al (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98(3):548–553

    Article  CAS  Google Scholar 

  18. Pigneux A, Perreau V, Jourdan E, Vey N, Dastugue N, Huguet F et al (2007) Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. Haematologica 92(10):1327–1334

    Article  CAS  Google Scholar 

  19. Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC et al (2004) Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 22(6):1087–1094

    Article  CAS  Google Scholar 

  20. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J et al (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17(12):3767–3775

    Article  CAS  Google Scholar 

  21. Prébet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn J-Y et al (2009) Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 27(28):4747–4753

    Article  Google Scholar 

  22. Ghimire KB, Shah BK (2014) Second primary malignancies in adult acute myeloid leukemia--a US population-based study. Anticancer Res 34(7):3855–3859

    PubMed  Google Scholar 

  23. Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D et al (2000) Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 96(4):1254–1258

    CAS  PubMed  Google Scholar 

  24. Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM et al (2014) Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 20(2):202–208

    Article  Google Scholar 

  25. Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S et al (2017) History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission. Am J Hematol 92(10):1032–1036

    Article  CAS  Google Scholar 

  26. Cerrano M, Itzykson R (2019) New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep 21(2):16

    Article  Google Scholar 

  27. Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG (2018) al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med 378(13):1189–1199

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Institut Paoli-Calmettes, Marseille, France

    B. Bouchacourt, M. A. Hospital, J. Rey, E. d’Incan, A. Charbonnier, B. Mohty, C. Saillard, S. Bonnet & A. Collignon

  2. Department of Clinical Research & Innovation, Biostatics & Methodology Unit, Institut Paoli-Calmettes, Marseille, France

    C. Zemmour

  3. Department of Pathology, Institut Paoli-Calmettes, Marseille, France

    V. Gelsi-Boyer & M. J. Mozziconacci

  4. Department of Hematology, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France

    D. Blaise & N. Vey

Authors
  1. B. Bouchacourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. A. Hospital
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Zemmour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Rey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. d’Incan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Charbonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Saillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Bonnet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Collignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. V. Gelsi-Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. J. Mozziconacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D. Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. N. Vey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. A. Hospital.

Ethics declarations

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 35.6 kb)

ESM 2

(DOCX 17 kb)

ESM 3

(DOCX 21 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bouchacourt, B., Hospital, M.A., Zemmour, C. et al. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome. Ann Hematol 99, 773–780 (2020). https://doi.org/10.1007/s00277-020-03922-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03922-w

Keywords

Search

Navigation